Navigation Links
Proteothera, Inc. Announces Scientific Advisors to Aid in Development of Novel Therapy for Acute Gout Attacks
Date:11/8/2015

ProteoThera, Inc., an early stage biotech platform company that is developing therapies for the local delivery of validated and FDA approved drugs, peptides, and small molecules to treat autoinflammatory diseases and tissue regeneration, today announced the team of scientific advisors who will guide the Company with their development of local delivery of a modified IL-1RA for the relief of pain for patients suffering from acute gout attacks.

“I believe that ProteoThera may be changing the paradigm for the traditional treatment of acute gout flares by potentially offering a safe and effective treatment for acute gout with an early onset of pain relief,” said Dr. Lee Simon, who serves as the Company’s acting Medical Director and lead scientific advisor. “The compilation of these renowned gout experts to serve as advisors for the acute gout therapy development program is a great step towards that goal.”

Advisors to ProteoThera’s acute gout therapy development program include the following experts:

  •     Lee Simon, M.D., Principal, SDG LLC, Former FDA Division Director, Division of Pulmonary, Allergy and Rheumatology Products
  •     Robert Terkeltaub, M.D., Professor of Medicine, University of California, San Diego
  •     Naomi Schlesinger, M.D., Professor of Medicine, Chief of Rheumatology, Rutgers University
  •     Joseph Flood, M.D., Columbus Arthritis Center

“We warmly welcome our new scientific advisors to the ProteoThera team,” said Patrick O’Donnell, President and Chief Executive Officer of ProteoThera. “I am confident that under guidance from this group of leaders in rheumatology with such varied foundations of expertise, our company will make great strides in furthering the development of our lead therapy and further prove out the significant value of our matrix-binding peptide technology platform for the local delivery of numerous commercially validated therapeutics.”

About ProteoThera, Inc.
ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology. The Company's transformative platform technology, a proprietary tissue matrix-binding (MB) peptide technology, is being developed to improve clinical efficacy and safety of FDA approved and validated therapeutics to create a new paradigm in the treatment of autoinflammatory diseases and in tissue regeneration.

The MB targeting technology was developed at Brigham and Women’s Hospital and Harvard Medical School. The MB technology can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally or subcutaneous delivered proteins, peptides, and small molecules. ProteoThera’s focus on previously validated or approved therapies greatly de-risks the clinical, regulatory, and commercial pathways. By keeping therapies where they are needed to enable therapeutic effect, the MB platform may also improve the safety profile by reducing or eliminating side effects associated with whole-body systemic exposure.

ProteoThera’s first development priority is the use of PRT-1000 (MB - Interleukin 1 Receptor Antagonist (MB-IL1RA) for treatment of acute gout pain. IL1RA is a potent cytokine inhibitor, already FDA approved for systemic administration in rheumatoid arthritis. Gout is a large and growing market with total gout drug sales projected to double to more than $2 Billion by 2018 in the US and Europe.
###

Read the full story at http://www.prweb.com/releases/2015/11/prweb13068177.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved


Related medicine news :

1. Pixel Film Studios announces the release of FCPX Toolbox Volume 4 which includes Essential Editing Tools for Final Cut Pro X Users.
2. First Choice Emergency Room Announces Dr. Andrew P. Kretschmer as Medical Director of Spring, Texas Facility
3. National Hot Dog and Sausage Council Announces Official Policy On ‘Hot Dog as Sandwich’ Controversy
4. Imagequantify.Com Announces New Iqbot For Quantitative Analysis Of Histological Imaging Data: Dab Stain Analysis
5. The National Center for Homeopathy Announces Constantine Hering, MD Dedication Ceremony
6. IRIS Announces Start of 2nd Annual 30/30 Retinal Screenings Campaign
7. RJ Young Announces Key Leadership Promotions & Additions
8. MTI-GlobalStem Announces Collaboration for First Commercial In Vitro Test System for Human Neuroprotection in Proteopathic Diseases, Such As Alzheimer’s and Parkinson’s
9. Dr. Michael Feiz Announces a Successful Outcome for Needlescopic Surgery Streamed Live at the 2015 ASMBS Conference
10. Career Training Academy Announces Relocation, Expansion for New Kensington Campus
11. Above and Beyond Family Center Announces Premier Public Reception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... 2017 , ... Connance, a leading provider of healthcare predictive ... analytics drive reimbursement optimization, with a focus on denial management and claims statusing, ... traditional approach to denied and underpaid claims leaves money on the table and ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... ... assessments and consulting services, has published a new eBook titled “ 5 Questions ... Bridge, MSc, Associate Research Analyst on the Genetic Test Evaluation (GTE) team, the ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos ... and a host of new options for today’s modern senior. Brazos Towers at ... active, independent lifestyle they love while offering them the services to support that lifestyle ...
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. ... Cincinnati, OH for leading-edge care, whether or not they have a referral. Dr. ... BIOLASE WaterLase® iPlus™ laser, she targets bacteria and damaged tissue without affecting the ...
(Date:6/20/2017)... ... June 20, 2017 , ... This ... program focused on finding product improvements that could reduce the occurrence of ... when they need help breathing or to provide medication. Sometimes, patient movement can ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... solutions, today announced that it will be presenting at the 7th ... AM PT. Erez Raphael , CEO, of DarioHealth will be ... will be held on June 6th & 7th, 2017 at the ... the small / micro-cap space. ...
Breaking Medicine Technology: